Timely Cancer Care Revolution Under Ayushman Bharat: Lancet Study InsightsA recent Lancet study has unveiled a significant improvement in the timely initiation of cancer treatment in India, particularly for patients covered under the Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana (AB-PMJAY).
on
February 6, 2025
NMC Greenlights Patient Appeals Against Doctors: What This Means for Medical Practitioners The National Medical Commission (NMC) has formally decided to empower patients and their families to file complaints against doctors for alleged medical negligence or misconduct, marking a pivotal shift in medical accountability. This decision, taken during a commission meeting on September 23, 2024, overturns the 2021 policy that restricted appeals to medical professionals only.
on
February 5, 2025
FDA Endorses JOURNAVX™ (Suzetrigine): A Peripheral Sodium Channel Blocker Redefining Acute Pain ManagementThe FDA has approved JOURNAVX™ (suzetrigine), Vertex Pharmaceuticals groundbreaking oral non-opioid therapy for moderate-to-severe acute pain. This marks the first new class of pain medication since Celebrex in 1998, targeting NaV1.8, a sodium channel critical for peripheral pain signaling.
on
February 4, 2025
Pune's GBS Outbreak: 158 Cases and Counting, WHO on the Ground !In a significant surge of Guillain-Barré Syndrome (GBS) in Pune, the total number of patients has now reached 158, with nine new cases reported on Sunday. Although no additional deaths have been recorded, bringing the toll to five, health authorities remain on high alert. Notably, patients on ventilator support decreased from 28 to 21, and ICU admissions dropped from 83 to 48. Hospitals report good recoveries, with 38 people discharged so far.
on
February 3, 2025
FDA Greenlights Novel NSAID/Triptan Combo for Rapid Migraine ReliefThe US Food and Drug Administration (FDA) has approved Symbravo (rizatriptan/meloxicam), a novel oral combination therapy for the acute treatment of migraine with or without aura in adults. Developed by Axsome Therapeutics, Symbravo leverages rapid absorption technology to target multiple migraine pathways, offering rapid and sustained relief.
on
February 1, 2025

Featured

FDA Approves Blujepa (Gepotidacin): First New Oral Antibiotic for uUTIs in Nearly 30 Years
Lorundrostat Shows Promise in Treating Uncontrolled Hypertension in Pivotal Trials
Kerala School Reports Viral Meningitis Cases, Health Authorities on High Alert
DCGI’s Renewed Mandate: Wiping Out Substandard Drugs, Supporting MSMEs, and Regulating Medical Devices
Delhi Sees Surge in H1N1 and Influenza B Cases

Participate in India’s healthcare revolution

Create ABHA & store all your medical records with Eka care (Govt of India ABDM approved PHR app)

Create ABHA ID

Popular topics

#

newfeature

#

Partnership

#

funding